Clinical Study
Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
Table 1
Administration schedule for each cohort of rapid infusion rituximab.
| | Rituximab 375 mg/m2 intravenously in 250 mL normal saline | |
| | Cycle 1 | | |
10 mL/h (first 1 hour) → 50 mL/h (second 1 hour) → 100 mL/h (until end of treatment) | | Cycle 2–8 | | | Cohort 1 | 50 mL/h (constant infusion, until end of treatment) | | Cohort 2 | 100 mL/h (constant infusion, until end of treatment) | | Cohort 3 | 150 mL/h (constant infusion, until end of treatment) | | Cohort 4 | 200 mL/h (constant infusion, until end of treatment) | | Cohort 5 | 250 mL/h (constant infusion, until end of treatment) | | Cohort 6 | 300 mL/h (constant infusion, until end of treatment) |
|
|
